Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sandoz’s Biosimilar Data-Bridging Plans For Zarxio Faced FDA Doubts

Jun 15 2015

• By Sue Sutter

Related Content

<em>Zarxio</em> Syringe’s Limitations May Delay Decision On <em>Neupogen</em> Interchangeability

Jun 15 2015

FDA’s Inaugural Biosimilar Review Bumpier Than First Appeared

Jun 15 2015

How To Label A Biosimilar? Copy The Reference Product, FDA Told Sandoz

Jun 15 2015

Sorry, Wrong Email: FDA’s ‘Oops’ Moment In The <em>Zarxio</em> Review

Jun 15 2015

<em>Zarxio</em> Clinical Development Timeline

Jun 15 2015

<em>Zarxio</em> Reviewers

Jun 15 2015

FDA Biosimilars Guidances Address Immunogenicity Studies, European Bridge Data, Analytics

Feb 13 2012

Biosimilar Guidances: Broader Populations Permitted; More Immunogenicity Requested

May 18 2015

Biosimilar User Fee Agreement Allows For Reliance On Foreign Clinical Data, FDAer Says

Dec 14 2011

Related Companies

Novartis AG

Amgen, Inc.

Additional Topics

United States Approvals BioPharmaceutical

More from United States

More from North America

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window